Reviews Doxorubicin hydrochloride


No reviews yet.

Adriamycin PFS Drug Description
Adriamycin PFS®
(doxorubicin hydrochloride) Injection, USP
FOR INTRAVENOUS USE ONLY

WARNING

Severe local tissue necrosis will occur if there is extravasation during
administration (see DOSAGE AND ADMINISTRATION). Doxorubicin must not
be given by the intramuscular or subcutaneous route.
Myocardial toxicity manifested in its most severe form by potentially fatal
congestive heart failure (CHF) may occur either during therapy or months to
years after termination of therapy. The probability of developing impaired
myocardial function based on a combined index of signs, symptoms and decline
in left ventricular ejection fraction (LVEF) is estimated to be 1 to 2% at
a total cumulative dose of 300 mg/m2 of doxorubicin, 3 to 5% at
a dose of 400 mg/m2, 5 to 8% at 450 mg/m2 and 6 to 20%
at 500 mg/m2. The risk of developing CHF increases rapidly with
increasing total cumulative doses of doxorubicin in excess of 400 mg/m2.
Risk factors (active or dormant cardiovascular disease, prior or concomitant
radiotherapy to the mediastinal/pericardial area, previous therapy with other
anthracyclines or anthracenediones, concomitant use of other cardiotoxic drugs)
may increase the risk of cardiac toxicity. Cardiac toxicity with doxorubicin
may occur at lower cumulative doses whether or not cardiac risk factors are
present. Pediatric patients are at increased risk for developing delayed cardiotoxicity.
Secondary acute myelogenous leukemia (AML) or myelodysplastic syndrome
(MDS) has been reported in patients treated with anthracyclines, including
doxorubicin (see ADVERSE REACTIONS). The occurrence of refractory secondary
AML or MDS is more common when anthracyclines are given in combination with
DNA-damaging anti-neoplastic agents or radiotherapy, when patients have been
heavily pretreated with cytotoxic drugs, or when doses of anthracyclines have
been escalated. The rate of developing secondary AML or MDS has been estimated
in an analysis of 8563 patients with early breast cancer treated in 6 studies
conducted by the National Surgical Adjuvant Breast and Bowel Project (NSABP),
including NSABP B-15. Patients in these studies received standard doses of
doxorubicin and standard or escalated doses of cyclophosphamide (AC) adjuvant
chemotherapy and were followed for 61,810 patient years. Among 4483 such patients
who received conventional doses of AC, 11 cases of AML or MDS were identified,
for an incidence of 0.32 cases per 1000 patient years (95% CI 0.16-0.57) and
a cumulative incidence at 5 years of 0.21% (95% CI 0.11-.41%). In another
analysis of 1474 patients with breast cancer who received adjuvant treatment
with doxorubicin-containing regimens in clinical trials conducted at University
of Texas M.D. Anderson Cancer Center, the incidence was estimated at 1.5%
at 10 years. In both experiences, patients who received regimens with higher
cyclophosphamide dosages, who received radiotherapy, or who were aged 50 or
older had an increased risk of secondary AML or MDS. Pediatric patients are
also at risk of developing secondary AML.
Dosage should be reduced in patients with impaired hepatic function.
Severe myelosuppression may occur.
Doxorubicin should be administered only under the supervision of a physician
who is experienced in the use of cancer chemotherapeutic agents.


DRUG DESCRIPTION



What are the possible side effects of doxorubicin (Adriamycin)?

If you experience any of the following serious side effects from doxorubicin, contact your doctor immediately:

an allergic reaction (including difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);
decreased bone marrow function and blood problems (extreme fatigue; easy bruising or bleeding; black, bloody or tarry stools; or fever, chills, or signs of infection);
congestive heart failure (difficulty breathing, fluid retention, chest...
Read All Potential Side Effects for Adriamycin PFS »




Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures
of Streptomyces peucetius var. caesius. Doxorubicin consists of
a naphthacenequinone nucleus linked through a glycosidic bond at ring atom 7
to an amino sugar, daunosamine. Chemically, doxorubicin hydrochloride is: 5,12-Naphthacenedione,
10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxylacetyl)-1-methoxy-,
hydrochloride (8S-cis)-. The structural formula is as follows:








Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix. The anthracycline ring is lipophilic, but the saturated end of the ring system contains abundant hydroxyl groups adjacent to the amino sugar, producing a hydrophilic center. The molecule is amphoteric, containing acidic functions in the ring phenolic groups and a basic function in the sugar amino group. It binds to cell membranes as well as plasma proteins.
Doxorubicin Hydrochloride for Injection, USP, is a sterile red-orange lyophilized powder.
Doxorubicin Hydrochloride Injection, USP, is a sterile parenteral, isotonic solution.Last reviewed on RxList: 9/11/2008




Adriamycin PFS Drug Description
Adriamycin PFS®
(doxorubicin hydrochloride) Injection, USP
FOR INTRAVENOUS USE ONLY

WARNING

Severe local tissue necrosis will occur if there is extravasation during
administration (see DOSAGE AND ADMINISTRATION). Doxorubicin must not
be given by the intramuscular or subcutaneous route.
Myocardial toxicity manifested in its most severe form by potentially fatal
congestive heart failure (CHF) may occur either during therapy or months to
years after termination of therapy. The probability of developing impaired
myocardial function based on a combined index of signs, symptoms and decline
in left ventricular ejection fraction (LVEF) is estimated to be 1 to 2% at
a total cumulative dose of 300 mg/m2 of doxorubicin, 3 to 5% at
a dose of 400 mg/m2, 5 to 8% at 450 mg/m2 and 6 to 20%
at 500 mg/m2. The risk of developing CHF increases rapidly with
increasing total cumulative doses of doxorubicin in excess of 400 mg/m2.
Risk factors (active or dormant cardiovascular disease, prior or concomitant
radiotherapy to the mediastinal/pericardial area, previous therapy with other
anthracyclines or anthracenediones, concomitant use of other cardiotoxic drugs)
may increase the risk of cardiac toxicity. Cardiac toxicity with doxorubicin
may occur at lower cumulative doses whether or not cardiac risk factors are
present. Pediatric patients are at increased risk for developing delayed cardiotoxicity.
Secondary acute myelogenous leukemia (AML) or myelodysplastic syndrome
(MDS) has been reported in patients treated with anthracyclines, including
doxorubicin (see ADVERSE REACTIONS). The occurrence of refractory secondary
AML or MDS is more common when anthracyclines are given in combination with
DNA-damaging anti-neoplastic agents or radiotherapy, when patients have been
heavily pretreated with cytotoxic drugs, or when doses of anthracyclines have
been escalated. The rate of developing secondary AML or MDS has been estimated
in an analysis of 8563 patients with early breast cancer treated in 6 studies
conducted by the National Surgical Adjuvant Breast and Bowel Project (NSABP),
including NSABP B-15. Patients in these studies received standard doses of
doxorubicin and standard or escalated doses of cyclophosphamide (AC) adjuvant
chemotherapy and were followed for 61,810 patient years. Among 4483 such patients
who received conventional doses of AC, 11 cases of AML or MDS were identified,
for an incidence of 0.32 cases per 1000 patient years (95% CI 0.16-0.57) and
a cumulative incidence at 5 years of 0.21% (95% CI 0.11-.41%). In another
analysis of 1474 patients with breast cancer who received adjuvant treatment
with doxorubicin-containing regimens in clinical trials conducted at University
of Texas M.D. Anderson Cancer Center, the incidence was estimated at 1.5%
at 10 years. In both experiences, patients who received regimens with higher
cyclophosphamide dosages, who received radiotherapy, or who were aged 50 or
older had an increased risk of secondary AML or MDS. Pediatric patients are
also at risk of developing secondary AML.
Dosage should be reduced in patients with impaired hepatic function.
Severe myelosuppression may occur.
Doxorubicin should be administered only under the supervision of a physician
who is experienced in the use of cancer chemotherapeutic agents.


DRUG DESCRIPTION



What are the possible side effects of doxorubicin (Adriamycin)?

If you experience any of the following serious side effects from doxorubicin, contact your doctor immediately:

an allergic reaction (including difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);
decreased bone marrow function and blood problems (extreme fatigue; easy bruising or bleeding; black, bloody or tarry stools; or fever, chills, or signs of infection);
congestive heart failure (difficulty breathing, fluid retention, chest...
Read All Potential Side Effects for Adriamycin PFS »




Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures
of Streptomyces peucetius var. caesius. Doxorubicin consists of
a naphthacenequinone nucleus linked through a glycosidic bond at ring atom 7
to an amino sugar, daunosamine. Chemically, doxorubicin hydrochloride is: 5,12-Naphthacenedione,
10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxylacetyl)-1-methoxy-,
hydrochloride (8S-cis)-. The structural formula is as follows:








Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix. The anthracycline ring is lipophilic, but the saturated end of the ring system contains abundant hydroxyl groups adjacent to the amino sugar, producing a hydrophilic center. The molecule is amphoteric, containing acidic functions in the ring phenolic groups and a basic function in the sugar amino group. It binds to cell membranes as well as plasma proteins.
Doxorubicin Hydrochloride for Injection, USP, is a sterile red-orange lyophilized powder.
Doxorubicin Hydrochloride Injection, USP, is a sterile parenteral, isotonic solution.Last reviewed on RxList: 9/11/2008




Adriamycin PFS Drug Description
Adriamycin PFS®
(doxorubicin hydrochloride) Injection, USP
FOR INTRAVENOUS USE ONLY

WARNING

Severe local tissue necrosis will occur if there is extravasation during
administration (see DOSAGE AND ADMINISTRATION). Doxorubicin must not
be given by the intramuscular or subcutaneous route.
Myocardial toxicity manifested in its most severe form by potentially fatal
congestive heart failure (CHF) may occur either during therapy or months to
years after termination of therapy. The probability of developing impaired
myocardial function based on a combined index of signs, symptoms and decline
in left ventricular ejection fraction (LVEF) is estimated to be 1 to 2% at
a total cumulative dose of 300 mg/m2 of doxorubicin, 3 to 5% at
a dose of 400 mg/m2, 5 to 8% at 450 mg/m2 and 6 to 20%
at 500 mg/m2. The risk of developing CHF increases rapidly with
increasing total cumulative doses of doxorubicin in excess of 400 mg/m2.
Risk factors (active or dormant cardiovascular disease, prior or concomitant
radiotherapy to the mediastinal/pericardial area, previous therapy with other
anthracyclines or anthracenediones, concomitant use of other cardiotoxic drugs)
may increase the risk of cardiac toxicity. Cardiac toxicity with doxorubicin
may occur at lower cumulative doses whether or not cardiac risk factors are
present. Pediatric patients are at increased risk for developing delayed cardiotoxicity.
Secondary acute myelogenous leukemia (AML) or myelodysplastic syndrome
(MDS) has been reported in patients treated with anthracyclines, including
doxorubicin (see ADVERSE REACTIONS). The occurrence of refractory secondary
AML or MDS is more common when anthracyclines are given in combination with
DNA-damaging anti-neoplastic agents or radiotherapy, when patients have been
heavily pretreated with cytotoxic drugs, or when doses of anthracyclines have
been escalated. The rate of developing secondary AML or MDS has been estimated
in an analysis of 8563 patients with early breast cancer treated in 6 studies
conducted by the National Surgical Adjuvant Breast and Bowel Project (NSABP),
including NSABP B-15. Patients in these studies received standard doses of
doxorubicin and standard or escalated doses of cyclophosphamide (AC) adjuvant
chemotherapy and were followed for 61,810 patient years. Among 4483 such patients
who received conventional doses of AC, 11 cases of AML or MDS were identified,
for an incidence of 0.32 cases per 1000 patient years (95% CI 0.16-0.57) and
a cumulative incidence at 5 years of 0.21% (95% CI 0.11-.41%). In another
analysis of 1474 patients with breast cancer who received adjuvant treatment
with doxorubicin-containing regimens in clinical trials conducted at University
of Texas M.D. Anderson Cancer Center, the incidence was estimated at 1.5%
at 10 years. In both experiences, patients who received regimens with higher
cyclophosphamide dosages, who received radiotherapy, or who were aged 50 or
older had an increased risk of secondary AML or MDS. Pediatric patients are
also at risk of developing secondary AML.
Dosage should be reduced in patients with impaired hepatic function.
Severe myelosuppression may occur.
Doxorubicin should be administered only under the supervision of a physician
who is experienced in the use of cancer chemotherapeutic agents.


DRUG DESCRIPTION



What are the possible side effects of doxorubicin (Adriamycin)?

If you experience any of the following serious side effects from doxorubicin, contact your doctor immediately:

an allergic reaction (including difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);
decreased bone marrow function and blood problems (extreme fatigue; easy bruising or bleeding; black, bloody or tarry stools; or fever, chills, or signs of infection);
congestive heart failure (difficulty breathing, fluid retention, chest...
Read All Potential Side Effects for Adriamycin PFS »




Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures
of Streptomyces peucetius var. caesius. Doxorubicin consists of
a naphthacenequinone nucleus linked through a glycosidic bond at ring atom 7
to an amino sugar, daunosamine. Chemically, doxorubicin hydrochloride is: 5,12-Naphthacenedione,
10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxylacetyl)-1-methoxy-,
hydrochloride (8S-cis)-. The structural formula is as follows:








Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix. The anthracycline ring is lipophilic, but the saturated end of the ring system contains abundant hydroxyl groups adjacent to the amino sugar, producing a hydrophilic center. The molecule is amphoteric, containing acidic functions in the ring phenolic groups and a basic function in the sugar amino group. It binds to cell membranes as well as plasma proteins.
Doxorubicin Hydrochloride for Injection, USP, is a sterile red-orange lyophilized powder.
Doxorubicin Hydrochloride Injection, USP, is a sterile parenteral, isotonic solution.Last reviewed on RxList: 9/11/2008




Adriamycin PFS Drug Description
Adriamycin PFS®
(doxorubicin hydrochloride) Injection, USP
FOR INTRAVENOUS USE ONLY

WARNING

Severe local tissue necrosis will occur if there is extravasation during
administration (see DOSAGE AND ADMINISTRATION). Doxorubicin must not
be given by the intramuscular or subcutaneous route.
Myocardial toxicity manifested in its most severe form by potentially fatal
congestive heart failure (CHF) may occur either during therapy or months to
years after termination of therapy. The probability of developing impaired
myocardial function based on a combined index of signs, symptoms and decline
in left ventricular ejection fraction (LVEF) is estimated to be 1 to 2% at
a total cumulative dose of 300 mg/m2 of doxorubicin, 3 to 5% at
a dose of 400 mg/m2, 5 to 8% at 450 mg/m2 and 6 to 20%
at 500 mg/m2. The risk of developing CHF increases rapidly with
increasing total cumulative doses of doxorubicin in excess of 400 mg/m2.
Risk factors (active or dormant cardiovascular disease, prior or concomitant
radiotherapy to the mediastinal/pericardial area, previous therapy with other
anthracyclines or anthracenediones, concomitant use of other cardiotoxic drugs)
may increase the risk of cardiac toxicity. Cardiac toxicity with doxorubicin
may occur at lower cumulative doses whether or not cardiac risk factors are
present. Pediatric patients are at increased risk for developing delayed cardiotoxicity.
Secondary acute myelogenous leukemia (AML) or myelodysplastic syndrome
(MDS) has been reported in patients treated with anthracyclines, including
doxorubicin (see ADVERSE REACTIONS). The occurrence of refractory secondary
AML or MDS is more common when anthracyclines are given in combination with
DNA-damaging anti-neoplastic agents or radiotherapy, when patients have been
heavily pretreated with cytotoxic drugs, or when doses of anthracyclines have
been escalated. The rate of developing secondary AML or MDS has been estimated
in an analysis of 8563 patients with early breast cancer treated in 6 studies
conducted by the National Surgical Adjuvant Breast and Bowel Project (NSABP),
including NSABP B-15. Patients in these studies received standard doses of
doxorubicin and standard or escalated doses of cyclophosphamide (AC) adjuvant
chemotherapy and were followed for 61,810 patient years. Among 4483 such patients
who received conventional doses of AC, 11 cases of AML or MDS were identified,
for an incidence of 0.32 cases per 1000 patient years (95% CI 0.16-0.57) and
a cumulative incidence at 5 years of 0.21% (95% CI 0.11-.41%). In another
analysis of 1474 patients with breast cancer who received adjuvant treatment
with doxorubicin-containing regimens in clinical trials conducted at University
of Texas M.D. Anderson Cancer Center, the incidence was estimated at 1.5%
at 10 years. In both experiences, patients who received regimens with higher
cyclophosphamide dosages, who received radiotherapy, or who were aged 50 or
older had an increased risk of secondary AML or MDS. Pediatric patients are
also at risk of developing secondary AML.
Dosage should be reduced in patients with impaired hepatic function.
Severe myelosuppression may occur.
Doxorubicin should be administered only under the supervision of a physician
who is experienced in the use of cancer chemotherapeutic agents.


DRUG DESCRIPTION



What are the possible side effects of doxorubicin (Adriamycin)?

If you experience any of the following serious side effects from doxorubicin, contact your doctor immediately:

an allergic reaction (including difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);
decreased bone marrow function and blood problems (extreme fatigue; easy bruising or bleeding; black, bloody or tarry stools; or fever, chills, or signs of infection);
congestive heart failure (difficulty breathing, fluid retention, chest...
Read All Potential Side Effects for Adriamycin PFS »




Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures
of Streptomyces peucetius var. caesius. Doxorubicin consists of
a naphthacenequinone nucleus linked through a glycosidic bond at ring atom 7
to an amino sugar, daunosamine. Chemically, doxorubicin hydrochloride is: 5,12-Naphthacenedione,
10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxylacetyl)-1-methoxy-,
hydrochloride (8S-cis)-. The structural formula is as follows:








Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix. The anthracycline ring is lipophilic, but the saturated end of the ring system contains abundant hydroxyl groups adjacent to the amino sugar, producing a hydrophilic center. The molecule is amphoteric, containing acidic functions in the ring phenolic groups and a basic function in the sugar amino group. It binds to cell membranes as well as plasma proteins.
Doxorubicin Hydrochloride for Injection, USP, is a sterile red-orange lyophilized powder.
Doxorubicin Hydrochloride Injection, USP, is a sterile parenteral, isotonic solution.Last reviewed on RxList: 9/11/2008




Adriamycin PFS Drug Description
Adriamycin PFS®
(doxorubicin hydrochloride) Injection, USP
FOR INTRAVENOUS USE ONLY

WARNING

Severe local tissue necrosis will occur if there is extravasation during
administration (see DOSAGE AND ADMINISTRATION). Doxorubicin must not
be given by the intramuscular or subcutaneous route.
Myocardial toxicity manifested in its most severe form by potentially fatal
congestive heart failure (CHF) may occur either during therapy or months to
years after termination of therapy. The probability of developing impaired
myocardial function based on a combined index of signs, symptoms and decline
in left ventricular ejection fraction (LVEF) is estimated to be 1 to 2% at
a total cumulative dose of 300 mg/m2 of doxorubicin, 3 to 5% at
a dose of 400 mg/m2, 5 to 8% at 450 mg/m2 and 6 to 20%
at 500 mg/m2. The risk of developing CHF increases rapidly with
increasing total cumulative doses of doxorubicin in excess of 400 mg/m2.
Risk factors (active or dormant cardiovascular disease, prior or concomitant
radiotherapy to the mediastinal/pericardial area, previous therapy with other
anthracyclines or anthracenediones, concomitant use of other cardiotoxic drugs)
may increase the risk of cardiac toxicity. Cardiac toxicity with doxorubicin
may occur at lower cumulative doses whether or not cardiac risk factors are
present. Pediatric patients are at increased risk for developing delayed cardiotoxicity.
Secondary acute myelogenous leukemia (AML) or myelodysplastic syndrome
(MDS) has been reported in patients treated with anthracyclines, including
doxorubicin (see ADVERSE REACTIONS). The occurrence of refractory secondary
AML or MDS is more common when anthracyclines are given in combination with
DNA-damaging anti-neoplastic agents or radiotherapy, when patients have been
heavily pretreated with cytotoxic drugs, or when doses of anthracyclines have
been escalated. The rate of developing secondary AML or MDS has been estimated
in an analysis of 8563 patients with early breast cancer treated in 6 studies
conducted by the National Surgical Adjuvant Breast and Bowel Project (NSABP),
including NSABP B-15. Patients in these studies received standard doses of
doxorubicin and standard or escalated doses of cyclophosphamide (AC) adjuvant
chemotherapy and were followed for 61,810 patient years. Among 4483 such patients
who received conventional doses of AC, 11 cases of AML or MDS were identified,
for an incidence of 0.32 cases per 1000 patient years (95% CI 0.16-0.57) and
a cumulative incidence at 5 years of 0.21% (95% CI 0.11-.41%). In another
analysis of 1474 patients with breast cancer who received adjuvant treatment
with doxorubicin-containing regimens in clinical trials conducted at University
of Texas M.D. Anderson Cancer Center, the incidence was estimated at 1.5%
at 10 years. In both experiences, patients who received regimens with higher
cyclophosphamide dosages, who received radiotherapy, or who were aged 50 or
older had an increased risk of secondary AML or MDS. Pediatric patients are
also at risk of developing secondary AML.
Dosage should be reduced in patients with impaired hepatic function.
Severe myelosuppression may occur.
Doxorubicin should be administered only under the supervision of a physician
who is experienced in the use of cancer chemotherapeutic agents.


DRUG DESCRIPTION



What are the possible side effects of doxorubicin (Adriamycin)?

If you experience any of the following serious side effects from doxorubicin, contact your doctor immediately:

an allergic reaction (including difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);
decreased bone marrow function and blood problems (extreme fatigue; easy bruising or bleeding; black, bloody or tarry stools; or fever, chills, or signs of infection);
congestive heart failure (difficulty breathing, fluid retention, chest...
Read All Potential Side Effects for Adriamycin PFS »




Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures
of Streptomyces peucetius var. caesius. Doxorubicin consists of
a naphthacenequinone nucleus linked through a glycosidic bond at ring atom 7
to an amino sugar, daunosamine. Chemically, doxorubicin hydrochloride is: 5,12-Naphthacenedione,
10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxylacetyl)-1-methoxy-,
hydrochloride (8S-cis)-. The structural formula is as follows:








Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix. The anthracycline ring is lipophilic, but the saturated end of the ring system contains abundant hydroxyl groups adjacent to the amino sugar, producing a hydrophilic center. The molecule is amphoteric, containing acidic functions in the ring phenolic groups and a basic function in the sugar amino group. It binds to cell membranes as well as plasma proteins.
Doxorubicin Hydrochloride for Injection, USP, is a sterile red-orange lyophilized powder.
Doxorubicin Hydrochloride Injection, USP, is a sterile parenteral, isotonic solution.Last reviewed on RxList: 9/11/2008





Other reviews about Doxorubicin hydrochloride on wordpress

Nanodiamonds Sparkle Delivering Drugs Without Side Effects
  by sandco
Northwestern University researchers have shown that nanodiamonds -- much like the carbon structure as that of a sparkling 14 karat diamond but on a much smaller scale -- […]


Aldesleukin
  by hijadoo
U.S. BRAND NAMES — Proleukin®PHARMACOLOGIC CATEGORY Biological Response ModulatorDOSING: ADULTS — Refer to individual protocols.Renal cell carcinoma: I.V.: 600,000 int. units/kg every 8 hours for a maximum of […]


We're Back
  by Eugene Sepulveda
(Community Matters) We're back in Houston. Michael is starting his first round of chemo this week. Today they'll insert the arm catheter and we'll sit through various training […]


Drugs
  by trooperg
The chemotherapy treatment regimen that is being used to work on my Mantle Cell Lymphoma is Rituxan and Hyper-CVAD. The term 'hyper' refers to the hyperfractionated nature of the […]


ALERT: Mitoxantrone (Novantrone) – heart problems
  by Thixia
  Information for Healthcare Professionals Mitoxantrone Hydrochloride (marketed as Novantrone and generics)   FDA ALERT [7/29/2008]:     FDA is informing health care professionals about additional recommendations for cardiac monitoring and reminding of […]


Dictionary of Cancer....(from: NCI)
  by fanymutiacahyani
A type of monoclonal antibody used in cancer detection or therapy. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells. AAP An enzyme that […]


Partnering Profile: Eisai
  by silico
How many partners does Eisai have? Like many pharmaceutical companies Eisai does not list the number of partners it has. Some idea of the strength of partnering within […]


Eisai
  by silico
How many partners does Eisai have? Like many pharmaceutical companies Eisai does not list the number of partners it has. Some idea of the strength of partnering within […]


Liposomal doxuribicin : MYOCET
  by powersteph65
So many people have been so kind and left wonderful messages. I am going through the side effects at the moment but promise I will answer every single […]


Oncology and Hematology
  by medtextfree
ONCOLOGY AND HEMATOLOGY Acute Leukemia Amyloidosis Approach to the Patient with Anemia Aplastic Anemia Breast Cancer Chronic Leukemia Hodgkin's Disease Inherited Disorders of Blood Coagulation Approach to the Patient with Leukocytosis Approach to the Patient with Lymphadenopathy Multiple Myeloma Non-Hodgkin's […]



Other reviews about Doxorubicin hydrochloride on web:

This page contains brief information about doxorubicin hydrochloride and a collection of links to more information about the use of this drug, related research results, and ... Doxorubicin Hydrochloride - National Cancer Institute


Doxorubicin (INN, pronounced /ˌdɒksəˈruːbəsɪn/; trade name Adriamycin; also known as hydroxydaunorubicin) is a drug used in cancer chemotherapy. Doxorubicin - Wikipedia, the free encyclopedia


S UBSTANCE P ROFILES R EPORT ON C ARCINOGENS ,E LEVENTH E DITION Adriamycin® (Doxorubicin Hydrochloride) CAS No. 23214-92-8 Reasonably anticipated to be a human carcinogen First Listed in the ... Eleventh Report on Carcinogens


Learn about the prescription medication Adriamycin PFS (Doxorubicin hydrochloride), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Adriamycin PFS (Doxorubicin hydrochloride) Drug Information: Uses ...


Adriamycin solution a form of doxorubicin hydrochloride is used in the treatment of cancers. Luekaemia, wilmis tumour and stomach cancer. Adriamycin Solution - Doxorubicin hydrochloride - Cancer Drug ...


DOXORUBICIN HYDROCHLORIDE: PRODUCT IDENTIFICATION. CAS NO. 23214-92-8 (parent) 25316-40-9 (hydrochloride) DOXORUBICIN HYDROCHLORIDE


View and buy high purity Doxorubicin hydrochloride from Tocris Bioscience, the leading worldwide supplier of high performance life science reagents Doxorubicin hydrochloride | [CAS 25316-40-9] | Tocris Bioscience ...


1 Doxorubicin Hydrochloride for Injection, USP Doxorubicin Hydrochloride Injection, USP FOR INTRAVENOUS USE ONLY WARNING 1. Severe local tissue necrosis will occur if there is ... Doxorubicin Hydrochloride for Injection, USP


DOXORUBICIN HYDROCHLORIDE is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia etc.. Doxorubicin - Serum Institute of India.


Each mL contains Doxorubicin hydrochloride 2 mg, sodium chloride 0.9%, water for injection q.s. pH adjusted with hydrochloric acid or sodium hydroxide, pH 2.5 to 4.5. Doxorubicin Official FDA information, side effects and uses.





Featured Reviews

Reviews Oxytrol

Oxytrol Drug Description Oxytrol (oxybutynin) Transdermal System Patch DRUG DESCRIPTION What are the possible side effects of oxybutynin transdermal (Oxytrol)? Get emergency medical help if you have any of these signs of an allergic...
Read More  |  Review This
Reviews Esterified Estrogens and Methyltestosterone

Estratest Drug Description ESTRATEST®‡ and ESTRATEST® H.S.‡ (esterified estrogens and methyltestosterone) Tablets ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER Close clinical surveillance of all women...
Read More  |  Review This
Reviews Cloderm

Cloderm Drug Description Cloderm® Cream, 0.1% (clocortolone pivalate) For Topical Use Only DRUG DESCRIPTION What are the possible side effects of clocortolone topical (Cloderm)? Get emergency medical help if you have any of...
Read More  |  Review This
Reviews AdreView

AdreView Drug Description AdreView (iobenguane I 123) Injection for Intravenous Use DRUG DESCRIPTION What are the possible side effects of iobenguane I-123 (AdreView)? Get emergency medical help if you have any of these signs of...
Read More  |  Review This
Reviews Amino Acid Injection with Electrolytes

Aminosyn II 8.5% Drug Description Aminosyn® II 8.5% WITH ELECTROLYTES Sulfite-Free AN AMINO ACID INJECTION WITH ELECTROLYTES Flexible Plastic Container DRUG DESCRIPTION Aminosyn® II 8.5% WITH ELECTROLYTES, Sulfite-Free, (an...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....